Andrew Hunter
Hospitalist · Seattle, WANPI 1982066544
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. Among hospitalist clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 17 payments — averaging $26.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$88
- Novo Nordisk$80
- Medtronic$69
- Lilly USA, LLC$54
- Novartis$35
- Regeneron Healthcare Solutions, Inc.$29
- plus $99 from 5 others
What the payments were for
- Food & beverage$455100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 3 | $88 |
| Novo Nordisk | 4 | $80 |
| Medtronic | 1 | $69 |
| Lilly USA, LLC | 2 | $54 |
| Novartis | 1 | $35 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| Exact Sciences | 1 | $25 |
| Tandem Diabetes Care, Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Dexcom, Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
How this compares
$455 in reported general payments places this provider in the 95th percentile of 661 hospitalist providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 12 | $820 |
| Atorvastatin Calcium | 41 | $468 |
| Quetiapine Fumarate | 12 | $281 |
| Levothyroxine Sodium | 18 | $186 |
| Escitalopram Oxalate | 11 | $173 |
| Sertraline Hcl | 15 | $171 |
| Losartan Potassium | 18 | $152 |
| Amlodipine Besylate | 34 | $141 |
| Trazodone Hcl | 13 | $123 |
| Lisinopril | 12 | $120 |
| Rosuvastatin Calcium | 13 | $100 |
| Tamsulosin Hcl | 11 | $82 |
| Citalopram HbrCitalopram Hydrobromide | 11 | $49 |
Paid to pharmacies, not to this prescriber.
Other hospitalist in Seattle
- James BarnesSeattle$12K
- Usman NaseerSeattle$8K
- Bryce JohnsonSeattle$4K
- Benjamin WolpawSeattle$3K
- John van TaunaySeattle$1K
- Preetham KumarSeattle$1K
- Neha DeshpandeSeattle$1K
- Amrit LambaSeattle$884
- Danh NgoSeattle$705
- Jay BrahmbhattSeattle$700
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.